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Abstract 
 
Since the 1990s, when opioids started to be grossly over-prescribed, almost 450,000 
people have died as a direct result of opioid abuse in the United States.  This study analyzes the 
role the opioid crisis has in the decreasing life expectancy in the United States, a troubling trend 
given the enormous and growing national healthcare expenditure. Employing a multiple 
decrement model and national life expectancy tables, this paper removes the opioid-related 
mortality and develops a new life expectancy model. The actuarial analysis of the observed and 
estimated life expectancies reveals the impact of opioid-related deaths: overall, U.S persons are 
losing 153 days of life. For some groups of the population the situation is even worse, such as for 
non-Hispanic white males whose life expectation is reduced by 261 days.  
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Introduction 
Life expectancy is a measure of how long a person can expect to live, on average. It 
summarizes the diseases, behavioral and lifestyle choices, dietary customs, and intentional and 
unintentional deaths that impact how long a person lives. Despite advances in cardiovascular 
diseases and other leading causes of death and ballooning healthcare expenditures, the life 
expectancy in the US has decreased since 2014 for three consecutive years1. The opioid crisis has 
greatly contributed to that decline (Muenning et al 2018). While more developed and wealthier 
countries tend to have higher life expectancies, the US is last among G7 countries and 28th out of 
35 OECD countries (OECD 2019).  
 
Figure 1: OECD Life Expectancies at Birth 
 
 
 
1 Preliminary data for 2018 shows a small increase in life expectancy (Kochanek, Anderson, and 
Arias 2020) 
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 Given this troubling trend, it is critical to have a rigorous understanding of opioid-related 
morbidity. From 1999-2018, 446,032 people have died because of an opioid overdose (CDC 
WONDER; See Appendix B for query parameters). US adults consume about 80% of all opioids 
in the world, and one out of every three adults in the country use opioids (Rummans, Burton, and 
Lawson 2018). This health crisis arose out of three waves (CDC 2020). First, in the 1990s 
pharmaceutical companies touted opioids as an effective and safe treatment for chronic pain, 
leading to a huge rise in prescriptions. Then, in 2010 overdoses started to rise, and the use of 
heroin increased. The third wave hit in 2013 when synthetic opioids, such as fentanyl, flooded 
illicit markets.  
 
Not everyone in the population has been affected equally. Middle-aged non-Hispanic 
whites have seen sharp rises in mortality and morbidity (Case and Deaton 2015). Furthermore, 
different types of opioids have impacted different population groups. Prescription opioids have 
previously driven mortality for whites, while illicit opioids, such as heroin, have affected 
minorities more. Those dynamics are changing rapidly with tighter regulations around 
prescriptions and the introduction of more potent and more deadly synthetic opioids, which are 
often abundant in illicit markets. Understanding this crisis is imperative for the federal and state 
governments as a large amount of tax revenues is appropriated to healthcare related expenditures. 
Health insurers and individual consumers also face significant costs due to opioid abuse.   
 
Prior research has attempted to characterize opioid mortality. Measuring mortality related 
to a specific condition can be challenging due to the dependent nature of causes of mortality. 
Case and Deaton (2015) report on the particular impact of the opioid crisis on mortality for 
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particular age groups and geographies. Muenning et al. (2018) also analyze the downward 
pressure on life expectancy due to opioids as a consequence of broad socio-economic trends.  
This study contributes to this growing body of work by obtaining the independent probabilities 
of cause specific mortality.  
 
To effectively measure a given illness’ mortality impact on life expectancy, the 
independent probability of being affected by it needs to be decoupled from every other possible 
illness that a person can get. For example, to be able to know how likely it is that a person will 
be affected by an opioid overdose, one must first know how likely it is for a person to not be 
affected by anything else. A multiple-decrement actuarial analysis, modeled by Lemaire (2005), 
accurately measures these probabilities. This technique has not been used in the recent medical 
literature.  
Results 
 
After applying the multiple decrement analysis on the CDC 2017 life expectancy model 
(Arias and Xu 2019), the latest available, to remove opioid-related mortality, the results show 
that the average US person loses 153.1 days due to opioid abuse (Table 1). The impact is much 
higher for males than females: 198.8 and 100.3 days, respectively.  
 
Table 1 
Impact of Opioid Abuse on Life Expectancy at Birth 
Population   Impact (Days Lost) 
United States; All   153.1 
United States; Females  100.3 
United States; Males     198.8 
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 The situation is alarming for everyone; yet, it is more alarming for some groups. Table 2 
shows the results categorized by sex, race, and origin. As suggested by Case and Deaton (2015), 
non-Hispanic whites are more impacted by opioid abuse. At 204 potential days of life lost, Non-
Hispanic whites lose almost twice as many days of life compared to non-Hispanic blacks, and 
almost three times as many as Hispanics. While still very concerning, Hispanics are the least 
impacted, with 76 days of life lost. The distinction by origin and not just race is important, as 
Arias and Xu (2019) note the significant difference between the groups in terms of life 
expectancy. The distinction between males and females is also drastic. Across all groups, 
females fare significantly better than males. Males face a life expectancy reduction about double 
or more of that of females. For Hispanic males, the reduction is three times as worse as Hispanic 
females, with 108 and 37 days lost, respectively. It is possible that these results are slightly 
underestimates as some opioid-related deaths were not considered as their age was unknown. 
Also, some studies suggest official opioid mortality data is significantly underestimated (Lowder 
et al, 2018). 
 
Table 2 
Impact of Opioid Abuse on Life Expectancy at Birth by Race/Origin 
Population   Impact (Days Lost)   
White; Non-Hispanic  203.9   
White Females; Non-Hispanic 137.3   
White Males; Non-Hispanic 261.4   
Black; Non-Hispanic  110.9   
Black Females; Non-Hispanic 69.2   
Black Males; Non-Hispanic 147.5   
Hispanic   75.9   
Hispanic Females  36.8   
Hispanic Males   107.9   
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The reduction to life expectancy is not constantly decreasing across ages, nor is it the 
highest at birth. Paradoxically, life expectancy increases marginally with age at first.  This is due 
to the fact that surviving past the first few years of life increases the chance of living longer 
compared to life expectations at birth. Similarly, the impact on life expectancy from opioids 
increases marginally in the first decade or so. Most groups have the same trend. Figure 2 shows 
the pattern across age for the overall US population. At age 12, US persons lose the most days of 
life: 154 days (0.8 days more than at birth). Table 3 shows the maximum reduction of life 
expectancy due to opioids for each group that occurs at different ages. Non-Hispanic black and 
white males lose the most potential life as they grow up to age 17, where the reduction is almost 
2 days more, both. For Hispanic females the impact on life expectancy is almost continually 
decreasing, reaching its peak at age 3.  
 
Figure 2 
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Table 3 
Maximum Impact on Life Expectancy  
Population   Impact (Days Lost) Age Increase 
United States; All  153.9 12 0.8 
United States; Females  100.6 1 0.4 
United States; Males  200.1 17 1.3 
White; Non-Hispanic  205.0 13 1.0 
White Females; Non-Hispanic 137.7 13 0.5 
White Males; Non-Hispanic 263.0 17 1.6 
Black; Non-Hispanic  111.7 1 0.9 
Black Females; Non-Hispanic 69.4 1 0.2 
Black Males; Non-Hispanic 149.0 1 1.6 
Hispanic   76.3 14 0.4 
Hispanic Females  37.0 3 0.1 
Hispanic Males   108.6 14 0.7 
  
Opioid abuse has been frequently discussed in terms of a middle age crisis. Table 4 
shows the concentration of opioid deaths by 10-year age groups for 2017 data. The age group 
most heavily affected is 30-39-year-old people who account for almost 28% of all opioid related 
deaths. However, describing this health crisis as one that mostly affects middle-aged persons 
would not be appropriate. The 35-45 grouping, which includes the literal midpoint of life only 
accounts for 26%. The broader 30-50 age grouping includes 50% of opioid related deaths. 
Opioid abuse affects adults of all ages fairly similarly.  
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Table 4 
Deaths by Age Segment 
Age Grouping  Deaths 
0-9  0.1% 
10-19  1.1% 
20-29  20.9% 
30-39  27.6% 
40-49  20.8% 
50-59  20.3% 
60-69  7.8% 
70-79  1.0% 
80+  0.3% 
   
Middle-Aged Crisis?  
35-45  25.5% 
30-50  50.4% 
 
 
Discussion 
 
If opioid overdoses were its own category, it would be considered the 10th leading cause 
of death in the US after separation from unintentional injuries and suicides (WISQARS 2020). 
Further, 70% of opioid-related deaths occur among people 50 and younger. The country is losing 
tens of thousands of valuable and productive members of society each year. A loss of almost half 
a year, and in some cases over two thirds of a year, of life expectancy is very alarming. From the 
1950s to 2014 life expectancy steadily increased, but then decreased for three continuous years 
until 2017. Over 50% of that decline is attributed to unintentional injuries and suicides, of which 
opioid overdoses are part of, according to Kochanek, Anderson, and Arias (2020).  The authors 
also note preliminary reports that indicate a life expectancy of 78.7 years in 2018, a 0.1 rise from 
2017. However, they also note that the small rise is only 25% due to a decrease in unintentional 
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injuries. Further, opioid overdoses decreased by less than 2% from 47,600 in 2017 to 46,802 in 
2018 (Wilson et al 2020). Wilson et al also note that the death rate for synthetic opioid increased 
by 10% from 2017 to 2018, while the rates for prescription-opioids and heroin decreased 4% and 
14%, respectively.  Unfortunately, it cannot be said that the opioid crisis is abating.  
 
As the results show, this crisis does not impact all groups equally. Non-Hispanic white 
males are the most affected group of the population and special attention needs to be given to 
them. Interventions needs to be designed within cultural and racial context that address broader 
structural and social health determinants.  Substance abuse treatments, prescription monitoring 
programs, distribution of naloxone, and partnerships with public safety need to be evaluated.  
 
Methodology 
 To assess how much life expectancy would increase if opioid-related mortality were 
removed, the independent probability of dying from anything but opioids needs to be calculated. 
Surviving all possible causes of death (excluding opioids) is the complement. Integrating that last 
probability equation over all years of life yields the life expectancy at birth. A description of the 
methods and data sources continues below.  
 
Step 1: Indep-P(death not opioids) = 1 – [1 – P(death)]^[P(death not opioids)/P(death)] 
 
Step 2: 1 – (step 1)  
 
Step 3: ∫ ((𝑠𝑡𝑒𝑝	2) ∗ 𝑓𝑜𝑟𝑐𝑒	𝑜𝑓	𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 ∗ 𝑡)𝑑𝑡!	#	$%  
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In step 3, the limit of ∞ changes in practice because is the current limit on human life is 116 
years (Senda 2019).  
 
This integration cannot be calculated with discretized data. However, as modeled by 
Oblander, Park, and Lemaire (2016) on suicide rates in Japan and South Korea and by Lemaire 
(2005) on the impact of firearm deaths on life expectancy in the United States, calculations can 
be performed using discrete life expectancy tables. Mortality data can be obtained from the 
Center for Disease Control and Prevention’s Wide-ranging Online Data for Epidemiologic 
Research (WONDER) and segregated by sex, age, and race.  
 
To begin, the total probability of death nqx(t) needs to be separated by cause, or 
decrement. For this study, decrement (1) will be death by opioid, and decrement (2) will be all 
else. Thus: nqx(t) = nqx(1) + nqx(2). One-year probabilities for each year of age ( x = 0,1,2,…) are 
considered. For example, 1q3(1) is the single year probability of dying due to opioids at age 3. 
When n = 1, 1qx(t) is denoted as qx(t) (omitted n). However, the two probabilities are dependent on 
each other. For example, to die of opioid overdose a person must have survived all other causes. 
So, given that a person has survived up to age x, qx(1) translates to the dependent probability of 
dying from age x to x+1 from opioid-related overdose. As a result of this inter-dependence, if the 
opioid-related mortality (qx(1)) decreases then the mortality of all else would increase (qx(2)). 
Additionally, a standard uniform distribution of deaths is assumed for total mortality and the 
opioid decrement. See Appendix B for specific formulas and descriptions.		
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 For the calculations, qx( 𝜏), the probability of dying between ages x and x + 1, is obtained 
directly from the CDC’s 2017 life expectancy table. Next, qx(1), the dependent probability of 
dying due to opioids is taken from the CDC WONDER platform. Death classifications followed 
the International Classification of Diseases, Tenth Revision (ICD-10) codes. See Appendix B for 
parameters.  From the complement qx(2) is readily obtained. As previously explained, the 
independent probabilities are necessary. With UDD, an exponential interpolation can be used to 
obtain the independent probabilities or absolute rates of decrement qx’(1)  and qx’(2). 
 
Next, a new life table can be developed to observe survival rates if opioid abuse ceased in 
the US. To begin, the modified number of people alive at each age, represented by lx’(t), needs to 
be mapped out. Starting with age at x = 0 years, it will be truncated at x = 85+ years. By 85, 
opioid related deaths are very uncommon. At x = 0, the table will consider a group of 100,000 
people alive. After a year, lx+1’(t) can be derived from multiplying lx’(t) by the probability for a 
person aged x to continue to live, which is the complement of qx(t). Th new number of deaths for 
each age x, dx’, is calculated by the product of people alive at the beginning of the year, lx’(t), and 
qx’(2). 
 
The previous allows for the calculation of the aggregate number of years lived by those 
alive at the beginning of each year, or total person-years lived Lx', until the start of the next year. 
With the UDD assumption, those who passed away live half a year, on average. Thus, when all 
person-years lived above age x are summed and then divided by the number alive at the 
beginning of the age-year x, the expectation of life is derived. The life expectation at birth, once 
opioid mortality is removed, ex', is the sum of the total person-years lived from birth until death, 
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divided by the number of people alive at x = 0. Finally, ex' and all other calculations can be 
compared to the original life table and opioid mortality reports to understand the impact of the 
opioid crisis.  
 
Conclusion 
 
An actuarial multiple decrement analysis shows that opioid related mortality accounts for 
a 153 day, or 0.42 year, reduction in life expectancy in the United States as of 2017. Males face a 
reduction in life expectancy twice as large as that of females. Across ethic/racial groups, non- 
Hispanic whites are the most impacted, but all groups face a significant loss of life. A large 
majority of deaths are concentrated in people 50 and younger, resulting in a significant cost to 
society. Further, deaths due to opioid overdoses are often preceded by extended periods of  
addiction. With synthetic opioids flooding black markets, it is no longer just an over-prescription 
issue. Significant and multi-faceted interventions are urgently needed to tackle this crisis.  
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Appendix A: Literature Review on Opioid-Related Mortality 
 
Life expectancy is a commonly used metric to compare the health status of nations’ 
citizens. It summarizes the diseases,  behavioral and lifestyle choices, dietary customs, and 
intentional or unintentional deaths that impact how long a person, on average, lives in a given 
country. Among countries in the OECD, the United States ranks poorly. At a life expectancy at 
birth of 78.6 years, it ranks behind countries that spend a small fraction of their GDP on their 
healthcare system compared to the US (OEDC 2017). 
 
For many decades, life expectancy in the US had been rising, albeit not as fast as in other 
rich countries (Muenning et al, 2018. In absence of “war, famine, and disease outbreaks,” 
countries should see fairly linear improvements in life expectancy. This projection accounts for 
the general advancements in healthcare technologies and lower mortalities that come with time. 
Dowel et al (2017) also report that for three decades up until 2000, the US had seen an average 
annual rise in life expectancy of 0.2 years. From 2000 to 2014, that rise decreased to 0.15 years. 
Most alarmingly, recent statistics show that the trend is now reversed. Haskins (2019) reports 
that for the past three years, life expectancy in the US has been revised down. OEDC (2019) 
confirm that in 2014 it was reported at 78.9 years. But as of 2017, life expectancy is now at 78.6. 
 
Case and Deaton (2015) also noted the very particular and worrisome trend that no other 
developed country was experiencing. They coined the term “deaths of despair” to describe the 
general sharp rise in mortality and morbidity that non-Hispanic whites (and particularly less 
educated whites) in the US were seeing. Case and Deaton highlight the opioid crisis and its 
related mortality as a significant contributor. Opioids were widely prescribed to treat real 
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prevalent pain in society, yet they started to quickly be overprescribed and misused. Consequent 
regulation then drove substitution to heroin which was becoming cheaper and widely available.  
Hansen and Netherland (2016) also notice the growing concern over  Americans turning to 
heroin when prescriptions were tightened. Muenning et al (2018, 1626) also note opioid-
associated mortality as a weight on life expectancy, discussing how in 2016 over 60,000 deaths 
were reported to be due to opioids. Rudd et al (2016) from the CDC, emphasize the drastic 
increases in fatal drug overdoses. Since 2000 to 2014, drug-overdoses have risen by almost a 1.5 
factor. And in just 2013 to 2014, mortality rates for prescribed opioids rose by 9%, heroin rose 
by 26%, and illicit synthetic opioids such as fentanyl rose by 80%.  
 
While Hansen and Netherland (2016) concur with Case and Deaton (2015) on the rise of 
opioid-related mortality, they argue that it is not just a problem for middle-aged non-Hispanic 
Whites in the US. Similarly, Haskins (2019) discusses how the opioid crisis and related “deaths 
of despair” are rooted in socio-economic determinants. Hansen and Netherlands (2016) posit that 
while the prescription opioid crisis does primarily impact white communities, black and Hispanic 
communities have been severely affected by heroin use.  Muenning et al (2018) argue that the 
opioid epidemic that is currently disproportionally affecting non-Hispanic whites sits on top of a 
“broad effect among all groups in the United States, not just less-educated whites.” Synthetic 
opioids, like fentanyl, also affect black and Hispanic communities drastically. Those 
communities who have historically been more affected by heroin use than their white 
counterparts, who were prescribed opioids much more frequently, are now exposed to cheaper, 
stronger and more available synthetics.  
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But even as the current literature show alarming mortality associated with opioids, some 
studies suggest the numbers might be underestimated. In Indiana, Lowder et al (2018) studied a 
large under-reporting of overdose-related deaths as deaths caused by opioids. They found that 
from 2011-2016, “57.7% of accidental overdose deaths were unspecified and 34.2% involved 
opioids”. But of the unspecified deaths, over 80% were actually due to opioids. Further, different 
death-classification protocols across the country present issues. For example, states with 
decentralized medical examiner systems like Louisiana, Pennsylvania, Alabama, Montana, 
Indiana, and Delaware, saw over one third of overdose-related deaths reported as unspecified. 
Parallelly, Barocas et all (2018) also note a large underreporting of opioid abuse in 
Massachusetts due to possible sigma and systemic error.  
 
Studies on life expectancy generally use CDC mortality reports from the National Vital 
Statistics System (NVSS). Death are categorized using the International Classification of 
Diseases, Tenth Revision. However, Iwanicki et al (2018) compared the quality of NVSS data to 
reported poison center calls. NVSS is the most complete data set, as all deaths are legally 
required to be reported to it. However, each case does not include many specifics and there is a 
one to two year lag before national reports are issued. On the other hand, calls to poison centers 
offer much more limited samples but have more detailed information. This is of particular 
interest when discerning between prescription opioid deaths and synthetic and illicit opioid 
deaths.  
 
The current medical literature that measures impact in life expectancy does not have a 
consensus on how to do so. Dowell et all (2017) calculate differences in life expectancy at birth 
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by partitioning using the change in the rate of deaths from unique causes for each age group for 
2000 vs 2015. In contrast, Case and Deaton (2015) calculate deaths that would have been 
prevented from 1999 to 2013 by comparing real mortality rates observed per year with the 
proportions that would have been seen per year if mortality had decreased in the same way seen 
from 1979 to 1998. Because they use age-group averages and not individual age mortalities, 
some of their observed results can be attributed to statistical bias. Another study in Ontario, 
Canada by Gomes et al (2014) uses a different method as well. The authors estimate years of life 
lost, as opposed to lives saved, or deduced life expectancy at birth directly.  
 
Lemaire (2005) introduces an actuarial multiple decrement technique to capture the direct 
impact on life expectancy by firearm deaths in the US. This method can be replicated to 
understanding opioid-related deaths and life expectancy. This paper uses this methodology as it 
is a better fit to identify causal relationships that impact mortality rates as it does not rely on age 
group averages.  
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Appendix B: Technical Notes 
 
Uniform Distribution of Deaths : Linear interpolation of deaths across time intervals 
 
UDD assumed for total mortality	and	the	opioid	decrement	:	
tqx  = !& * tqx    for 0 ≤ 𝑡 ≤ 𝑛.	
 
qx(1) : Dependent probability of dying due to opioids between x and x + 1 
 
 Opioid-related morality rates were obtained from the CDC WONDER platform for National 
Center for Health Statistics. Death classifications followed ICD-10 codes X40–44 
(unintentional), X60–64 (suicide), X85 (homicide), and Y10–Y14 (undetermined intent). For 
deaths related to drug overdoses, opioid mortality was coded with T40.0 (Opium), T40.1 
(Heroin), T40.2 (Other opioids), T40.3 (Methadone), T40.4 (Other synthetic narcotics), and 
T40.6 (Other and unspecified narcotics). Some deaths can be due to multiple opioids; thus, 
categories are not mutually exclusive, but the over estimation effect is minimal. This protocol is 
defined by the Substance Abuse and Mental Health Services Administration and is standard 
reporting practice for how the CDC reports data (Scholl et all, 2019).  
 
qx(2) : Dependent probability of dying not due to opioids between x and x + 1 
 
 
Obtained from the difference between qx(	𝜏) and qx(1) . 
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qx'(2): Independent probability of dying not due to opioids between x and x + 1 
 
An exponential interpolation between 1 and qx(2) based on the ratio of deaths that are due to 
opioid abuse: 
qx’(2) = 1 – [1 - qx(t) ]^( qx(2)/ qx(t)) 
 
lx' : Modified number of people surviving to age x, without the opioid decrement  
 
 
Starting using radix of 100,000 at age 0: 
lx' = lx-1' * (1 - qx-1'(2)) 
Because 85 is the last year of age for which reliable population data is available, the new table 
show aggregated data for that cohort. Logically, at x = 85+ qx( 𝜏) and qx’(2) will equal 1, as death is 
certain for the infinite interval past 85. q85+(1) is derived from the total number of deaths from 
opioids divided by the population over 85 years.  
 
dx' : Modified number deaths between ages x and x + 1, without the opioid decrement 
 
dx' = lx' * qx'(2) 
At  x = 85+, deaths cover all of the remaining population.   
 
Lx' : Total person-years lived between ages x and x + 1, without the opioid decrement 
 
Obtained by counting one year for everyone that survived and a half year for everyone that died 
based on a uniform distribution of deaths throughout the year.  
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Lx' = lx’ * 1 + dx' * 0.5 
For x = 0, infancy mortality is heavily skewed towards the beginning of the year. A separation 
factor (a ratio of infant deaths for year n from infants born in year n-1), f, employed by a birth 
cohort method is provided in the technical notes of the 2017 Life Tables (Arias and Xu 2019). 
The following formula can then be used for L0': 
L0' = l0’ * f + l1’ * ( 1-f ) 
For the person-years lived calculation at the end of the table the following equation is required as 
employed by Oblander, Park, and Lemaire (2016): 
 
∞L85’ = ( E[T85] * l85’ ) / ( 1 - ∞q85(1) ) 
 
Tx' : Modified total number of person-years lived above age x 
 
 
Sum of all Lx'  from age x and above. 
 
 
ex' :  Modified expectation of life at age x 
 
ex' = Tx' / lx' 
 
From the difference of ex' and ex (from the original 2017 life table), the expected change in life 
expectancy if opioid-related deaths had not occurred is obtained. A year is considered as 365.25 
days.
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